Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma

Completed · Phase 2

Conditions studied: Neuroblastoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma.

Key facts

Study ID

NCT00003737

Run by

Memorial Sloan Kettering Cancer Center

People needed

30

Starts

1999-01-01

Expected to finish

2006-09-01

Last updated by the study team

2013-06-25

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.